All In Biotech

Drug Trial Radar · NCT05595460

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

21

Actual

Start

Oct 10, 2022

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
RayzeBio, Inc.Industry
Sponsor type
Industry
First posted
Oct 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Conditions

  • SCLC,Extensive Stage

Interventions

  • RYZ101 Dose Level 1Drug

    Dose Level 1

  • RYZ101 Dose Level 2Drug

    Dose Level 2

  • RYZ101 Dose Level 3Drug

    Dose Level 3

  • RYZ101 Dose Level -1Drug

    Dose Level -1

  • AtezolizumabDrug

    Atezolizumab

  • CarboplatinDrug

    Carboplatin

  • EtoposideDrug

    Etoposide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2DTime frame: 42 days of study treatment
  2. Safety and tolerability of RYZ101 in combination with SoCTime frame: Up to 50 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Facility

    Los Angeles, California

  • Research Facility

    San Francisco, California

  • Research Facility

    Jacksonville, Florida

  • Research Facility

    Miami, Florida

  • Research Facility

    Orlando, Florida

  • Research Facility

    Iowa City, Iowa

  • Reserach Facility

    Lexington, Kentucky

  • Research Facility

    Grand Rapids, Michigan

  • Research Facility

    Rochester, Minnesota

  • Research Facility

    St Louis, Missouri

  • Research Facility

    Omaha, Nebraska

  • Research Facility

    Salt Lake City, Utah

  • Research Facility

    San Juan, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.